Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries

Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries

Summary

GBI Research, the leading business intelligence provider, has released its latest research, '‘Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'’, which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the hypertension in the major developed markets.The report includes -
- Disease overview, as well as treatment algorithms and treatment use patterns
- Market size and forecast for the hypertension market from 2013-2020
- Major marketed products for hypertension along with a heat map of product performance
- In-depth pipeline analysis for global pipeline in hypertension along with clinical trial failure rate analysis
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the hypertension therapeutics market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Pathophysiology 8
2.2 Etiology 9
2.3 Signs and Symptoms 9
2.4 Co-Morbidities and Complications 10
2.5 Diagnosis 11
2.5.1 Office Blood Pressure Monitoring 11
2.5.2 Ambulatory Blood Pressure Monitoring 11
2.5.3 Home Blood Pressure Monitoring 11
2.5.4 Miscellaneous Methods 11
2.5.5 Diagnosis of Target Organ Damage 12
2.5.6 Diagnosis of Hypertension in Pregnancy 12
2.6 Classification 12
2.7 Epidemiology 13
2.8 Prognosis 14
2.9 Treatment and Management 14
2.9.1 Treatment Strategy 15
3 Marketed Products 19
3.1 Approved Products 19
3.1.1 Norvasc (amlodipine besylate) - Pfizer 19
3.1.2 Micardis (telmisartan) - Boehringer Ingelheim 21
3.1.3 Tekturna (aliskiren) - Novartis/Speedel 22
3.1.4 Benicar (olmesartan medoxomil) - Daiichi Sankyo 24
3.1.5 Diovan (valsartan) - Novartis 25
3.1.6 Cozaar (losartan) - Merck 27
3.1.7 Exforge (amlodipine + valsartan) - Novartis 29
3.2 Comparative Efficacy and Safety 31
4 Product Pipeline 33
4.1 Overall Pipeline 33
4.2 Pipeline Analysis by Molecules Type 34
4.3 Pipeline Analysis by Mechanism of Action Type 35
4.4 Clinical Trial Failure Rate 37
4.5 Patient Enrollment and Clinical Trial Size 39
4.6 Clinical Trial Duration 40
4.7 Promising Drug Candidates in Pipeline 41
4.7.1 LCZ696 (AHU-377 + valsartan) - Novartis 41
5 Market Forecast 42
5.1 Introduction 42
5.2 Global Market 42
5.3 North America 44
5.3.1 Treatment Usage Patterns 44
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Revenue 46
5.4 Top Five European Countries 47
5.4.1 Treatment Usage Patterns 47
5.4.2 Annual Cost of Therapy 48
5.4.3 Market Revenue 49
5.5 Japan 50
5.5.1 Treatment Usage Patterns 50
5.5.2 Annual Cost of Therapy 50
5.5.3 Market Revenue 51
5.6 Drivers and Barriers 52
5.6.1 Drivers 52
5.6.2 Barriers 52
6 Deals and Strategic Consolidations 54
6.1 Licensing Deals 56
6.1.1 Bristol-Myers Squibb Enters into Licensing Agreement with Kyowa Hakko Kirin for Coniel in China 57
6.1.2 Takeda Pharma Enters into Licensing Agreement with Arbor Pharma for Edarbi and Edarbyclor 57
6.1.3 Lorus Therapeutics Enters into Licensing Agreement with Zor Pharma 57
6.1.4 Nippon Shinyaku Signs Licensing Agreement with Eli Lilly 57
6.2 Co-development Deals 58
6.2.1 AnGes Enters into Co-development Agreement with BioLeaders for Hypertension Vaccine 59
6.2.2 Takeda Enters into Co-development Agreement with Covance 59
6.2.3 Boehringer Ingelheim Enters into an Agreement with Vitae Pharma 59
6.2.4 NicOx Expands Research Collaboration with Merck 59
7 Appendix 60
7.1 Market Forecasts to 2020 60
7.2 All Pipeline Drugs by Phase 63
7.2.1 Discovery 63
7.2.2 Preclinical 64
7.2.3 Phase I 66
7.2.4 Phase II 74
7.2.5 Phase III 77
7.3 Abbreviations 82
7.4 References 84
7.5 Methodology 87
7.5.1 Coverage 87
7.5.2 Secondary Research 88
7.5.3 Primary Research 88
7.5.4 Therapeutic Landscape 88
7.5.5 Geographical Landscape 91
7.5.6 Pipeline Analysis 91
7.6 Expert Panel Validation 91
7.7 Contact Us 91
7.8 Disclaimer 91

1.1 List of Tables
Table 1: Anti-Hypertensives Market, Possible Co-Morbidities 10
Table 2: Anti-Hypertensives Market, Blood Pressure Classification in Adults 12
Table 3: Anti-Hypertensives Market, Prevalence Rate (%) 14
Table 4: Anti-Hypertensives Market, Initiation of Treatment 15
Table 5: Anti-Hypertensives Market, Lifestyle Management 16
Table 6: Anti-Hypertensives Market, Major Developed Market, Forecast Data, 2013-2020 60
Table 7: Anti-Hypertensives Market, US, Forecast Data, 2013-2020 60
Table 8: Anti-Hypertensives Market, UK, Forecast Data, 2013-2020 61
Table 9: Anti-Hypertensives Market, France, Forecast Data, 2013-2020 61
Table 10: Anti-Hypertensives Market, Germany, Forecast Data, 2013-2020 61
Table 11: Anti-Hypertensives Market, Italy, Forecast Data, 2013-2020 62
Table 12: Anti-Hypertensives Market, Spain, Forecast Data, 2013-2020 62
Table 13: Anti-Hypertensives Market, Japan, Forecast Data, 2013-2020 62
Table 14: Anti-Hypertensives Market, Canada, Forecast Data, 2013-2020 63
Table 15: Anti-Hypertensives Market, Global, Developmental Pipeline, Discovery Phase 63
Table 16: Anti-Hypertensives Market, Global, Developmental Pipeline, Preclinical Phase 64
Table 17: Anti-Hypertensives Market, Global, Developmental Pipeline, Phase I 66
Table 18: Anti-Hypertensives Market, Developmental Pipeline, Phase II 74
Table 19: Anti-Hypertensives Market, Developmental Pipeline Phase III, 2013 77
Table 20: Anti-Hypertensives Market, Therapeutics, Abbreviations 82

1.2 List of Figures
Figure 1: Anti-Hypertensives Market, Global, Prevalence Rate (%), 2007-2010 13
Figure 2: Anti-Hypertensives Market, Treatment Algorithm, 2013 18
Figure 3: Anti-Hypertensives Market, Global, Norvasc (amlodipine besylate) Revenue ($bn), 2005-2013 20
Figure 4: Anti-Hypertensives Market, Global, Micardis (telmisartan), Revenue ($bn), 2005-2013 22
Figure 5: Anti-Hypertensives Market, Global, Tekturna (aliskiren) Revenue ($m), 2007-2013 23
Figure 6: Anti-Hypertensives Market, Global, Benicar (olmesartan), Revenue ($bn), 2005-2013 25
Figure 7: Anti-Hypertensives Market, Global, Diovan (valsartan) Revenue ($bn), 2005-2013 27
Figure 8: Anti-Hypertensives Market, Global, Cozaar (losartan), Revenue ($bn), 2005-2013 29
Figure 9: Anti-Hypertensives Market, Global, Exforge (amlodipine + valsartan), Revenue ($bn), 2007-2013 30
Figure 10: Anti-Hypertensives Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 32
Figure 11: Anti-Hypertensives Market, Global, Pipeline Distribution by Stage, Program Type and Route of Administration, 2013 33
Figure 12: Anti-Hypertensives Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 34
Figure 13: Anti-Hypertensives Market, Global, Pipeline by Mechanism of Action, 2013 35
Figure 14: Anti-Hypertensives Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development, 2013 36
Figure 15: Anti-Hypertensives Market, Global, Clinical Trial Failure Rate (%), 2013 37
Figure 16: Anti-Hypertensives Market, Global, Clinical Trial Failure Rate (%), 2006-2013 38
Figure 17: Anti-Hypertensives Market, Global, Clinical Trial Size (Participants), 2013 39
Figure 18: Anti-Hypertensives Market, Global, Pipeline Clinical Trial Duration (Months), 2013 40
Figure 19: Anti-Hypertensives Market, Global, Treatment Usage Patterns and Market Revenue ($bn), 2013-2020 43
Figure 20: Anti-Hypertensives Market, US and Canada, Treatment Usage Patterns, 2013-2020 44
Figure 21: Anti-Hypertensives Market, US and Canada, Annual Cost of Therapy ($), 2013-2020 45
Figure 22: Anti-Hypertensives Market, US and Canada, Market Revenue ($bn), 2013-2020 46
Figure 23: Anti-Hypertensives Market, Top Five European Markets, Treatment Usage Patterns, 2013-2020 47
Figure 24: Anti-Hypertensives Market, Top Five European Markets, Annual Cost of Therapy ($), 2013-2020 48
Figure 25: Anti-Hypertensives Market, Top Five European Markets, Market Revenue ($bn), 2013-2020 49
Figure 26: Anti-Hypertensives Market, Japan, Treatment Usage Patterns, 2013-2020 50
Figure 27: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2013-2020 51
Figure 28: Anti-Hypertensives Market, Japan, Market Revenue ($bn), 2013-2020 51
Figure 29: Anti-Hypertensives Market, Global Deals by Value, Year and Stage of Development, 2006-2013 54
Figure 30: Anti-Hypertensives Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2013 55
Figure 31: Anti-Hypertensives Market, Global, Licensing Deals by Geography, 2006-2013 56
Figure 32: Anti-Hypertensives Market, Global, Co-Development Deals by Region, Value ($m) and Year, 2006-2013 58
Figure 33: GBI Research Market Forecasting Model 90